

Consideration and allowance of claims 39 and 58-94 are respectfully requested at the earliest possible time.

Respectfully submitted,

**JOHN R. DePHILIPPO ET AL.**

1 November 2002

(Date)

By: 

**GARY D. COLBY, Ph.D., J.D.**

Registration No. 40,961

**AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.**

One Commerce Square

2005 Market Street, Suite 2200

Philadelphia, PA 19103

Telephone: 215-965-1200

Direct: 215-965-1285

Facsimile: 215-965-1210

E-mail: gcolby@akingump.com

Enclosures: Marked-Up Copy of Claim Amended  
Clean Copy of Claims, as Amended

U.S. Patent Application  
Serial No. 09/826,522

Attorney Docket No.  
10691-1

**Marked-Up Copy of Claim Amended  
in the Response to Restriction Requirement  
and Preliminary Amendment**

39. (Amended) A method of selecting a dose of an anti-oxidant composition for administration to a human, the method comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in at least ~~one gene~~ two genes selected from the group consisting of

- a) genes which encode an enzyme that catalyzes conversion of a toxic oxygen species to a less toxic oxygen species;
- b) genes which encode a protein that provides protection against oxidative stress;
- c) genes which encode a protein that induces production of a toxic oxygen species;
- d) genes which encode a protein that indirectly affects oxidative stress; and
- e) genes which encode a protein for which the level of expression of the protein is associated with oxidative stress,

whereby occurrence of any of the polymorphisms is an indication that a greater dose of the composition should be administered to the human; and

selecting a dose of the composition based on occurrence of the polymorphisms.